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We know that chromosomes are threadlike structures of nucleic acids and 
proteins, which are found in the nucleus of most living cells. They carry genetic 
information in the form of genes. Chromosomes are protected at their ends by a 
specialized structure called telomere. With each replicative cycle, the telomeres 
get shortened preventing uncontrolled replications. Telomeres perform several 
functions like protect the chromosome ends from sticking together, solve the end 
of replication problem, and limit the number of cell divisions. It is considered 
that telomeres are associated with cancer incidence and mortality. Telomere DNA 
has repetitive sequences (5′-TTAGGG-3′ in human), which is lengthened at the 
3′ end by a special ribonucleoprotein enzyme called telomerase. Short telomeres 
are associated with early senescence, genomic instability, and apoptosis of cells. 
Short telomeres can result due to several factors including environmental factors, 
external factors like smoking, stress, as well as due to mutations in the components 
of telomere or telomerase. Short telomeres are associated with several disorders and 
diseases, such as dyskeratosis congenita, aplastic anemia, pulmonary fibrosis, and 
even cancer. Thus, it is important to understand how telomeres are associated with 
these diseases and what can be done to prevent such conditions.
Keywords: aplastic anemia, dyskeratosis congenita, idiopathic pulmonary fibrosis, 
telomere, telomerase
1. Introduction
Over the years, it has been observed that many degenerative disorders are associ-
ated with telomere dysfunction. Telomeres are present at the end of chromosomes. 
They protect the chromosome ends and critical genetic information in the chromo-
some from degradation by acting as caps from fusing with other chromosomes [1]. 
We know that the replication machinery cannot completely copy the chromosome 
ends, which is called end replication problem. As a result, the telomeres get shorter 
with each replicative cycle that leads to cell senescence [2]. Short telomeres are 
associated with genome instability. Telomere dysfunction caused by defects in 
telomerase proteins is associated with genomic instability that increases genetic 
mutations characterized by an increased incidence of cancer and also high sensitiv-
ity to genotoxic compounds. Short telomeres activate a p53-dependent checkpoint, 
which leads to senescence and apoptosis of the cells [3–6]. Telomere shortening can 
be caused by some external factors also such as smoking, stress, poor health such as 
obesity, inflammation [7]. Telomere shortening is also accelerated due to chemical 
and physical environmental agents. Reactive oxygen species can produce modified 
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bases (mainly 8-oxoG) and single strand breaks in the genome. Oxidative damage 
can result from high incidence of guanine residues in telomeric DNA sequences [8]. 
Telomere shortening has been recognized as one of the important determinants 
behind senility and some diseases including—dyskeratosis congenita (DC), idio-
pathic pulmonary fibrosis (IPF) [9]. Telomere length is maintained by an enzyme 
called telomerase that adds telomeric repeats to the chromosome 3′-end using an 
RNA template. The enzyme is a ribonucleoprotein complex, which is inactive in 
somatic cells but active in stem cells and most cancer cells [10, 11]. Dysfunctional 
telomeres are recognized by many DNA damage response proteins leading to chro-
mosome fusions, genome instability and altered gene expression patterns [12, 13]. 
Several cellular processes including apoptosis, aging, carcinogenesis, and chromo-
some instability are caused as consequences of loss of telomeres [14, 15].
2. Telomeres
Hermann J. Muller and Barbara McClintock in the 1930s described the telomere 
as a protective structure of DNA present at the end of the chromosome [16]. It pro-
tects the chromosome structure. The human telomeres have repetitive 5′-TTAGGG-3′ 
subunits, associated with a variety of telomere-associated proteins. The structure 
consists of a portion of the double-stranded DNA with an overhanging 3′ G-rich end 
(Figure 1) [1, 16].
Human somatic cells enter replicative senescence after a limited number of 
replications. This occurs due to the end replication problem leading to shortening 
of telomeres [17]. In absence of this structure, the replication cycle stops and the 
end-to-end fusion of chromosomes may occur [18–20]. Telomeres are bound by 
a specialized protein complex called shelterin [21–24]. Due to the end replication 
problem, the telomeres shorten with each cell cycle, and these short telomeres 
induce the DNA damage response and activate the p−53 dependent checkpoint, 
leading to apoptosis or senescence (Figure 2A) [21]. But in case of germ cells or in 
cancer cells, telomere maintenance is observed likely due to the expression or reacti-
vation of telomerase, thus the replicative cycle of the cells continue.
The telomere shortening takes place as the eukaryotic DNA polymerases have no 
mechanism for synthesizing the final nucleotides present on the “lagging strand” 
of the double-stranded DNA. DNA polymerase synthesizes new DNA only from 
the 5′ → 3′ direction. The two strands of DNA are complementary, one strand is in 
5′ → 3′ direction, while the other is in 3′ → 5′. DNA polymerase cannot synthesize 
DNA in the 3′ → 5′ direction. The process is compensated by the use of Okazaki 
fragments. Okazaki fragments are short pieces of DNA that are synthesized in the 
5′ → 3′ direction from the 3′ → 5′ end as the replication fork moves. As RNA primer 
is required by DNA polymerase to synthesize new strand, each Okazaki fragment 
consists of an RNA primer followed by short DNA sequence. When the DNA 
polymerase reaches the chromosome end, the RNA primer is again placed, which 
Figure 1. 
3′ overhanging of telomere.
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is inevitably removed. But as the primer is removed, the DNA polymerase cannot 
synthesize the remaining bases leading to telomere shortening with each replicative 
cycle (Figure 2B) [16, 25, 26].
In addition to that several external factors can also affect telomere length and 
maintenance. Factors such as smoking, alcohol consumption, chemical and environ-
mental pollutants, radiation and many more can affect telomere length (Figure 2C).
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3. Telomerase
The telomerase enzyme is a ribonucleoprotein containing both RNA and protein. 
It functions as a reverse transcriptase that positively regulates the telomere length 
[21, 27, 28]. The ribonucleoprotein has two essential components: telomerase reverse 
transcriptase (hTERT), the catalytic component, and telomerase RNA component 
(hTERC or hTR) which provides the template for telomere addition. Telomerase 
synthesizes new telomeres by solving the end-replication problem (Figure 3) [29].
Biogenesis of telomerase in somatic cells requires the assembly of hTERT and 
hTR into a stable complex that can function at telomeres. hTR (RNA component 
of telomerase) contains a box H/ACA motif which regulates RNA trafficking and 
Figure 3. 
An image showing how telomerase elongates telomere ends progressively.
Figure 2. 
(A) Telomere shortening leads to DNA damage response. The DNA damage responses include apoptosis, senescence 
of the cell or genomic instability that can lead to cancer. (B) “Lagging strand” end-replication problem. With 
each replication cycle the ends of the chromosome get shortened as the final RNA primer at the 3′-end cannot be 
replaced with DNA. (C) External factors associated with telomere shortening and maintenance.
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stability. This H/ACA motif allows the hTR to associate with the dyskerin complex. 
This dyskerin complex is a four-protein core of dyskerin protein with another three 
nucleolar proteins—NOP10, NHP2, and GAR1 (Figure 4) [21, 30, 31]. Mutations 
in five out of six components that make up the telomerase ribonucleoprotein 
have been identified in humans causing telomere syndrome. These H/ACA RNAs 
can be divided into two groups. First, H/ACA small nucleolar RNAs (snoRNAs), 
that modifies ribosomal RNAs by accumulating in the nucleolus. Second, H/ACA 
small Cajal body-specific RNAs (scaRNAs) direct the modification of splicing 
RNAs by accumulating in Cajal bodies [32]. The difference in cellular trafficking 
between the two groups is attributable to the presence of another sequence motif, 
called Cajal body box or CAB box. They are the subnuclear sites of ribonucleo-
protein assembly and modification [33]. The hTR has both H/ACA motif and  
also CAB box.
Shelterin component of telomerase regulates the synthesis of telomeres. It regu-
lates the telomere length by forming t-loops whose formation is controlled by TRF2. 
TRF2 requires the help of other components such as TRF1 to function. Mutations in 
the shelterin components such as TRF2 and POT1 are found to be associated with 
short telomeres leading to such syndromes (Figure 5) [34].
A number of studies have revealed that in normal somatic cells the telomerase 
activity is almost absent. However a low level of telomerase activity has been found in 
mitotically active cells, including skin, lymphocytes, and endometrium. Telomerase 
enzyme is expressed in stem cells to maintain the telomere length all through their 
Figure 4. 
The essential telomerase components.
Figure 5. 
The shelterin complex.
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life cycle. About 90% of the cancer cells have short telomeres with increased levels of 
telomerase activity [18]. For example, about 75% cases of oral carcinomas, 80% of 
lung cancers, 84% of prostate cancers, 85% of liver cancers, 93% of breast cancers, 
94% of neuroblastomas, 95% of colorectal cancers, and 98% of bladder cancers have 
been found to be associated with increased levels of telomerase activity [35].
Telomerase transfection in normal cells can lead to the elongation of telomeres. 
For example, telomerase-negative normal cells, such as retinal pigment epithelial 
cells and foreskin fibroblasts, transfected with vectors encoding human hTERT 
show telomere elongation, but telomerase-negative control cells exhibit both 
telomere shortening and senescence [36].
Furthermore, mutations in the telomerase and telomere components lead to the 
syndromes of telomere shortening (Table 1).
4. Syndromes associated with short telomere
4.1 Dyskeratosis congenita (DC)
Dyskeratosis congenita (DC) is a rare progressive congenital disorder having 
a highly variable phenotype [38]. DC is a rare syndrome of premature aging. The 
term coined by clinicians based on a triad of mucocutaneous features that they 
found in male children. These are—leukoplakia of the oral mucosa, skin hyperpig-
mentation, and dystrophy of nails [39]. This triad was associated with premature 
mortality of children due to bone marrow failure in aplastic anemia. DC mainly 
affects the skin. But in nearly 80% of the cases, bone marrow failure also occurs. 
DC is also characterized by the predisposition of cancer. In serious forms, the life 
span can be significantly shortened.
Table 1. 
Human telomere shortening associated genes, their functions and mode of inheritance in dyskeratosis congenita [37].
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4.1.1 Genetics of the syndrome
In 1998, the gene encoding dyskerin, DKC1 was discovered. It was identified 
in X-linked families with the help of linkage and positional cloning. Dyskerin is a 
putative box H/ACA telomerase RNA binding protein [40]. The protein links with 
the telomerase RNA structure. The hTR has a box H/ACA motif and the X-linked 
DC patients have low levels of telomerase RNA component resulting in short 
telomeres. It is supported by the fact that mutations in the DKC1 gene disrupt the 
maturation and stability of hTR. Mutations in the dyskerin complex, NOP1O and 
NHP2 have also been identified in DC families [41, 42].
The best characterized form of dyskeratosis congenita is a result of one or more 
mutations in the gene DKC1 present on the long arm of X chromosome. This result 
in the X-linked recessive form of the disease also called Zinsser-Cole-Engman syn-
drome wherein the major protein affected is dyskerin [40]. Within the vertebrates, 
dyskerin is a key component of the telomerase RNA component (hTR) in the form 
of the H/ACA motif. This X-linked variety, like the NOP10 and NHP2 mutations, 
demonstrates shortened telomeres as a result of lower hTR concentrations [43, 44].
Recently, heterozygous mutations in the shelterin component TINF2 were 
identified in several cases of DC. Mutations in the TINF2 results in severe mani-
festations and usually present in children [34, 45]. Different organs show different 
types of defects in DC patients (Table 2).Many of these cells express telomerase, an 
enzyme that maintains telomeres.
Mutations in DKC1 can lead to significant declines in hTR levels, i.e. one fifth 
of the wild-type [46]. This is consistent with the fact that mutations in the DKC1 
Table 2. 
Defects in DC patients are most often seen in tissues in which cells divide rapidly, and often, many of these cells 
express telomerase, an enzyme that maintains telomeres.
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lead to accelerated phenotypes because of a loss of greater than half of the avail-
able telomerase. Mutations in the shelterin component TINF2 also lead to severe 
disease. This suggests that telomere defects are alone sufficient to cause dyskeratosis 
congenita (DC) [40, 42, 43].
Due to aplastic anemia when DC patients undergo bone marrow transplant, they 
frequently suffer with morbidity and mortality from pulmonary fibrosis and liver 
failure. This happens even when the patients seem to have intact function in these 
organs during the time of transplant [47, 48]. This happens due to the limited length 
of the telomeres in the patient’s lung and liver, and also the poor capacity of DNA 
damage repair after chemotherapy and radiation.
Nonmyeloablative bone marrow transplant should be considered in aplastic 
anemia, where there is mutation in the telomere or telomerase components [40].
4.1.2 DC patients are cancer prone
As many as 10% of the DC patients die due to the cancer diagnosis. DC is 
thought to be a cancer-prone disorder because of the underlying pathology 
of abnormal telomere maintenance. The link between DC and cancer is very 
interesting, because DC is associated with defects in telomere biology. Patients 
with DC have very short telomeres. Mutations have been identified in telomere 
biology genes. The United Kingdom Dyskeratosis Congenita Registry (DCR) data 
indicated that the crude rate of malignancy among approximately 300 patients 
was 10%. DC patients are at increased risk of myelodysplasia and acute leukemia 
[49]. Since aplastic anemia itself has an associated increased risk for transforma-
tion to acute myeloid leukemia, it is unclear whether DC patients with aplastic 
anemia have an added predisposition. DC patients also have increased incidence 
of squamous cell cancers of the skin and head and neck. In DC patients, these 
cancers are diagnosed at as early as the 2nd decade of the life. DC patients with 
cancer have a mean age at cancer diagnosis of 29 and a cumulative incidence of 
~40% by the age of 50.
4.1.3 Predisposition to cancer
Susceptibility to cancer seems counterintuitive due to the fact that in many 
known cancers reactivation of telomerase is actually a required step for malignancy 
to evolve however short telomeres do contribute to genome instability. In a disease 
like DC where telomerase is affected, it does not seem that cancer would be a com-
plication to result. But it is discussed that with critically short or absent telomeres, 
chromosomes will likely be attached together at their ends through the non-homol-
ogous end joining pathway (NHEJ). If this occurrence is common enough, then 
malignancy even without functional telomerase seems probable.
4.1.4 Haploinsufficiency of telomerase
Families with autosomal dominant dyskeratosis congenita show anticipation 
and have mutations in the telomerase RNA gene. A null mutation in motif D of the 
hTERT domain is associated with this phenotype. This mutation leads to haploin-
sufficiency of telomerase, and telomere shortening occurs despite the presence of 
telomerase (Figure 6) [50].
This finding shows the importance of telomere maintenance and telomerase 
dosage for maintaining tissue proliferative capacity. It has also relevance for 
understanding mechanisms of age-related changes. Telomere length limits the 
number of replication cycle of primary fibroblasts and has been associated with 
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cellular aging [50]. Short telomeres activate DNA damage response, which leads 
to apoptosis. It is the shortest telomere and not the average telomere length within 
a cell that is responsible for mediating the response that leads to cell death [51]. 
Mutations in the hTERT component can result in a complex phenotype of stem 
cell failure. This phenotype shows anticipation; it presents earlier and more 
severely with successive generations. The anticipation is due to haploinsufficiency 
of telomerase that results in progressive shortening of telomeres (Figure 7) [52]. 
The hTERT mutation results in haploinsufficiency of telomerase, which leads to 
shortening of telomeres across generations [49]. The number of these short telo-
meres is correlated with the severity of phenotypes expressed. The earlier onset 
of such phenotypes in later generations implicates that in bone marrow and other 
solid tissues the telomere length is short and in limiting proliferative capacity. 
This pattern of anticipation suggests that like aplastic anemia, this disorder might 
also affect the stem cells within the lung.
Figure 6. 
Telomere shortening despite the presence of telomerase. Mutations in the hTERT or hTR components of 
telomerase prevent them from extending the telomere length.
Figure 7. 
The figure depicts autosomal dominance mode of inheritance. The dark blue region represents mutant hTERT 
or hTR allele. Darker shades of black represent progressive telomere shortening leading to anticipation of 
phenotypes that is the age of onset becomes earlier with each generation.
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4.2 Aplastic anemia due to telomere shortening
Aplastic anemia arises when the body’s bone marrow does not make enough 
new blood cells. It can develop at any age. A number of diseases, conditions and 
factors can damage the blood-making stem cells in bone marrow and bring about 
aplastic anemia.
Aplastic anemia patients with shorter chromosome tips, or telomeres, have a 
lower survival rate and are much more likely to relapse after treatment than those 
with longer telomeres. Studies identified germline mutations in the hTR and 
hTERT components of the telomerase in ~3% of the adults with so-called aplastic 
anemia [52, 53]. In recent years, scientists have found that some patients suffering 
with severe aplastic anemia have extremely short telomeres in their blood cells. 
Telomeres are also known as molecular caps that protect the chromosomes ends 
from erosion. With each cell division they naturally become shorter, but telomeres 
can be rebuilt by enzymes. Telomere length is affected by genetic factors and 
environmental stressors. Patients with short telomeres suffer from morbidity and 
mortality even after the bone marrow transplant for the aplastic anemia [47, 54]. As 
these short telomeres lead to organ failures.
Patients with the short telomeres are also at greater risk for a conversion to bone 
marrow cancer (24%).
4.3 Idiopathic pulmonary fibrosis due to telomere shortening
Idiopathic pulmonary fibrosis has a predictable and progressive clinical 
course that ultimately leads to respiratory failure [55]. Although both genetic and 
environmental factors have been implicated, the cause of idiopathic pulmonary 
fibrosis (IPF) is unknown. IPF is the most common manifestation out of the 
other telomere-mediated disorders [56]. Germ line mutations in the telomerase 
hTERT and hTR component genes are the reason behind up to one-sixth of 
pulmonary fibrosis families [57]. The presence of telomerase mutations is sig-
nificant. As extra-pulmonary complications, affected individuals can suffer from 
bone marrow failure and cryptogenic liver cirrhosis due to telomere shortening. 
Evidence suggests that IPF results from autosomal dominant telomere syn-
dromes. Here with successive generations, the condition evolves from pulmonary 
fibrosis to a disorder of bone marrow failure. It is perhaps the most devastating 
of the idiopathic disorders in medicine.
IPF is an age-related disease. From the time of diagnosis, IPF patients live on 
average 3 years. Several clinical factors are known which are associated with the 
IPF. Age is the biggest with the great majority are diagnosed after the age of 60. It is 
also most frequently in males with a nearly 2:1 ratio [58].
4.3.1 IPF in dyskeratosis congenita patients
DC represents a more severe presentation of a spectrum of telomere syn-
dromes where IPF represents an attenuated form [40]. Pulmonary fibrosis in case 
of bone-marrow failure can be precipitated by pulmonary toxic drugs during of 
bone marrow transplant. For example, fatal pulmonary fibrosis in DC patients 
is caused by the alkylating agent busulfan used in myeloablative conditioning 
regimens [59]. Even without precipitating toxins, pulmonary fibrosis is a signifi-
cant and under-estimated complication of DC. In some DC patients, pulmonary 
fibrosis is the major cause of premature mortality in the absence of bone marrow 
failure [60].
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4.3.2 IPF is the most frequent manifestation of telomere-associated disease
In most cases, IPF is associated with telomere maintenance. Mutations in hTERT 
and hTR are the risk factors in 8–15% of familial cases of IPF [57, 61]. In about 3% 
of sporadic IPF cases, mutations in the telomerase genes are also found [53]. Here 
hTERT mutations frequency is higher than hTR mutations, but the mutant genes 
cannot be identified based on only clinical features [62]. Short telomeres are suf-
ficient to cause the common form of IPF [63].
The hTERT and hTR mutations result in short telomeres because of the loss of 
functions and the haploinsufficiency [56]. As compared to DC and aplastic anemia, 
the prevalence of IPF is more common, lung disease is the most common manifes-
tation of telomere-mediated disorders [64, 65]. Thus, although DC is specific for 
identifying individuals with telomere-mediated disease, it only can identify only a 
small subset, i.e. nearly 5% of all cases.
4.3.3 IPF patients with short telomeres without any mutations in telomerase
Although telomerase mutations are found in one-sixth of the families with IPF, 
short telomeres are found in other IPF patients without any mutations in the telom-
erase genes [58]. Significantly shorter telomeres are seen in case of sporadic IPF 
cases (those who report no family history) [61, 65]. Telomere shortening can be 
found in immune cells such as lymphocytes, granulocytes and also alveolar epithe-
lial cells, which implicate global telomere defect in such individuals. The observa-
tion suggests that individuals with shortest telomeres are more likely to develop IPF 
than normal individuals in the population [66]. These patients with short telomeres 
may be a risk factor for disease outside the lung. A subset of sporadic IPF that lack 
an apparent telomerase mutation also develops cryptogenic liver cirrhosis [57]. 
There is also relation between IPF and incidence of diabetes. IPF patients have 
about 3-fold increased incidence of diabetes compared to the age-matched controls 
[67]. In case of telomerase deficient mice, short telomeres cause defects in insulin 
secretion resulting in glucose intolerance. Therefore alongside IPF, short telomeres 
can be a risk factor for diabetes development [68]. Thus in sporadic IPF cases, the 
defect in telomere length may cause telomere-associated diseases outside of lung.
4.3.4 IPF patients with extra-pulmonary disorders
IPF patients and their relatives who carry telomerase mutations can develop 
telomere-mediated diseases, which are extra-pulmonary [57]. These are, bone-
marrow failure including macrocytosis of red blood cells, single lineage cytope-
nias, aplastic anemia, myelodysplastic syndromes, and acute myeloid leukemia 
[69, 70, 71]. In case of patients without DC, IPF and bone marrow failure are not 
considered as related conditions. But occurrence of these two together allows 
clinical identification of families carrying telomerase mutations. A recent find-
ing suggests that germ line defects in telomerase of a single family are associ-
ated with the occurrence of these two disorders together [62]. When present in 
successive generations, both the IPF and bone marrow failure syndrome together 
predicted the presence of an hTERT or hTR gene mutation in 10 out of 10 
families (100%).
Other than the bone marrow failure, IPF patients with telomerase mutations 
may also develop other complications of telomere-mediated disease like liver 
cirrhosis [50]. So, the IPF affected individuals are at a higher risk of developing 
extra-pulmonary diseases.
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4.4 Role of telomeres and telomerase in cancer
Short telomeres due to mutations in telomerase have been proposed to be associ-
ated with cancer. The concept seems counterintuitive as we know that telomerase 
activation is a required step for malignancy to occur in nearly 85% of the cases as it 
allows unlimited cell cycle without senescence. How telomerase reactivation occurs 
in case of cancer is not clear till date. Studies suggest mutations in two key posi-
tions of hTERT promoter region (C250T and C228T) cause enhanced expression 
of hTERT leading to enhanced telomerase activation (Table 3) [72, 73]. But this 
information needs to be investigated properly. Short telomeres can lead to genomic 
instability and also cancer via non-homologous end joining (NHEJ) of chromo-
somes. Mutations in the hTR or hTERT components of telomerase are associated 
with abnormally short telomeres leading to cancer. Mutations in several compo-
nents of telomerase such as DKC1, NOP10, NHP2, GAR1 or shelterin components 
such as TRF1, TRF2, POT1 can lead to short telomeres [30]. Absence or very short 
telomeres allow non-homologous chromosomes to join head to head. Syndromes 
associated with short telomeres such as dyskeratosis congenita, aplastic anemia are 
associated with cancer. It has been found that DC patients are cancer prone. They 
have increased risk of acute leukemia and myelodysplasia [49]. Aplastic anemia is 
also associated with acute myeloid leukemia. Patients also have increased risk of 
squamous cell cancers. Overexpression of TERT is also associated with increased 
cell proliferation in epidermal tumors and mammary carcinomas in mice [74].
Thus genomic instability due to loss of telomeres and overexpression of telomer-
ase probably play major roles in such cancer development.
5. Conclusion
Cellular aging eventually leads to cell death. It is the progressive decline of cells in 
resisting stress and other cellular damages. This leads to gradual loss of cellular func-
tions resulting in cell death. Telomere shortening is a major factor that is related with 
cellular aging. With age, the telomere length declines due to end replication problem, 
Table 3. 
Types of cancers associated with mutations in the telomerase hTERT promoter region.
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leading to cell senescence. It poses a barrier to the tumor growth but also results in 
the loss of cells with aging. When the caps of the chromosomes which are telomeres 
become critically short, it prevents cell cycle to continue leading to either cell senes-
cence or apoptosis. This cell cycle arrest occurs due to DNA damage proteins such as 
ATM, which become activated when telomere becomes critically shortened leading to 
activation of p53 dependent checkpoint. Mutations in the telomere or the telomerase 
components such as hTR or hTERT result in a broad spectrum of diseases present in 
children and adults. The onset and severity of these diseases are determined by the 
extent of telomere shortening. Usually the onset of cancer is associated with the activ-
ity of the telomerase holoenzyme, but with reduced telomeres due to affected telomer-
ase, the chromosomes may join by non-homologous end joining (NHEJ) and can lead 
to malignancy. This study shows that syndromes such as dyskeratosis congenita (DC), 
idiopathic pulmonary fibrosis (IPF), and aplastic anemia are caused by the telomere 
shortening. IPF syndrome is the most common manifestation of the telomere shorten-
ing. Thus this provides evidence that short telomeres are sufficient to cause common, 
age-related diseases. Treatment for these diseases involves organ transplantation such 
as liver, lung, bone marrow. Although this organ transplantation provides improved 
physical condition for patients, it does not address the actual cause, which is short 
telomeres. In recent times, telomerase activators such as TA-65 has gained commercial 
interest. It is also reported that sex hormones activate TERT transcription.
The understanding of the role of telomere and telomerase in aging and some 
diseases can open new possibilities in understanding the genetic factors that play 
important role in the origin and augmentation of several other diseases.
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